An online roadshow, was held on Tuesday (13/8), bringing together five innovative health-tech companies with leading Chinese industrial companies and investment entities to explore opportunities for investment and cooperation.
The event was jointly initiated and executed by SHENG Enterprises in cooperation with V-Next, a subsidiary of Shenzhen Stock Exchange.
Joyce Zhang of V-Next opened the event expressing the interest to promote Israel – China investment & cooperation in the health-tech sector.
SHENG’s managing Partner, Ilan Maor presented SHENG activities and the healthcare sector, as well as the health-tech industry and invited the Chinese investors to explore investment and cooperation in Israel.
The Israeli health-tech company presenting at the event were:
Arineta (www.arineta.com), an innovative Israeli company, develops and produces innovative cardiovascular imaging solutions. Based on the company’s proprietary Stereo CT technology, Arineta develops the world’s first dedicated single-heartbeat, whole heart Cardiovascular and Thoracic CT. Together with its Chinese partners, Arineta is about to launch the domestically produced equipment in China for its new generation of product, committed to improving the accessibility of coronary CT at reasonable cost with high quality and providing accurate screening diagnosis for patients with coronary diseases.
Medical Electronics Systems (https://mes-global.com/), is the world leader in automated semen analysis, the only company in the world with a full range of semen testing products from humans to animal husbandry, from clinical to household use.
Dormotech (www.dormotech.com) is a Digital Health company, specializing in monitoring and diagnosis of sleep disorders. A new generation of home diagnostic device that is personal, reusable, small, easy to use, and multi-channel, sophisticated and is designed to enable a new business model based on the new standards of digital health. The Device will dramatically change the sleep assessment scene for both adults and children.
Salignostics (www.salignostics.com) is focusing on the development of saliva based rapid diagnostics tests (RDT), utilizing a lateral flow immunoassay platform. The company’s platform is comprised of a “tool box” of technologies which amplify the saliva as a detectable body-fluid by overcoming different chemical and biological saliva related obstacles. Implementation of these technologies transforms saliva from a non-detectable to a detectable body-fluid.
Inretio (http://inretio.co.il/) focuses on improving the treatment of ischemic strokes caused by a clot blocking blood flow to the brain. The company addresses a significant challenge, with over 175,000 ischemic stroke patients in the US undergoing mechanical thrombectomy procedures every year. Inretion’s PREVA clot retriever is the 1st and only protective clot retriever using a distal basket, and can access distally to the clot, protecting the brain during the procedure from sub-clots, and allowing the complete removal of the clot and its fragments to ensure revascularization of the brain tissue.
